[
  {
    "id": "hyhel10-lysozyme",
    "challengeId": "lysozyme",
    "name": "HyHEL-10 Antibody",
    "slug": "hyhel10",
    "binderType": "antibody",
    "pdbId": "3HFM",
    "pdbUrl": "https://www.rcsb.org/structure/3HFM",
    "binderChainId": "H,L",
    "shortDescription": "Classic mouse antibody - one of the most studied antibody-antigen complexes",
    "helpArticleSlug": "hyhel10",
    "discoveryYear": 1984,
    "approvalStatus": "research_tool",
    "sortOrder": 0,
    "scores": {
      "plddt": 95.57,
      "ptm": 0.908,
      "iptm": 0.552,
      "ipSaeScore": -0.552,
      "pdockq": 0.742,
      "pdockq2": 0.115,
      "lis": 0.457
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "Y"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "d3l11-lysozyme",
    "challengeId": "lysozyme",
    "name": "D3-L11 Nanobody",
    "slug": "d3l11",
    "binderType": "nanobody",
    "pdbId": "6JB8",
    "pdbUrl": "https://www.rcsb.org/structure/6JB8",
    "binderChainId": "B",
    "shortDescription": "High-affinity camelid nanobody with unusual binding mode",
    "helpArticleSlug": "d3l11",
    "discoveryYear": 2019,
    "approvalStatus": "research_tool",
    "sortOrder": 1,
    "scores": {
      "plddt": 91.36,
      "ptm": 0.601,
      "iptm": 0.215,
      "ipSaeScore": -0.215,
      "pdockq": 0.739,
      "pdockq2": 0.015,
      "lis": 0.06
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "B"
      ]
    }
  },
  {
    "id": "cabhul5-lysozyme",
    "challengeId": "lysozyme",
    "name": "cAbHuL5 Camelid Nanobody",
    "slug": "cabhul5",
    "binderType": "nanobody",
    "pdbId": "4I0C",
    "pdbUrl": "https://www.rcsb.org/structure/4I0C",
    "binderChainId": "C,D",
    "shortDescription": "Binds to \u03b1-domain - inhibits amyloid fibril formation",
    "helpArticleSlug": "cabhul5",
    "discoveryYear": 2013,
    "approvalStatus": "research_tool",
    "sortOrder": 2,
    "scores": {
      "plddt": 85.66,
      "ptm": 0.631,
      "iptm": 0.224,
      "ipSaeScore": -0.224,
      "pdockq": 0.742,
      "pdockq2": 0.015,
      "lis": 0.075
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "B"
      ]
    }
  },
  {
    "id": "gfp-enhancer",
    "challengeId": "gfp",
    "name": "GFP Enhancer Nanobody",
    "slug": "gfp-enhancer",
    "binderType": "nanobody",
    "pdbId": "3K1K",
    "pdbUrl": "https://www.rcsb.org/structure/3K1K",
    "binderChainId": "C,D",
    "shortDescription": "Increases GFP brightness - widely used in imaging",
    "helpArticleSlug": "gfp-enhancer",
    "discoveryYear": 2009,
    "approvalStatus": "research_tool",
    "sortOrder": 0,
    "scores": {
      "plddt": 90.26,
      "ptm": 0.626,
      "iptm": 0.255,
      "ipSaeScore": -0.255,
      "pdockq": 0.741,
      "pdockq2": 0.018,
      "lis": 0.045
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "B"
      ]
    }
  },
  {
    "id": "lag16-gfp",
    "challengeId": "gfp",
    "name": "LaG16 Nanobody",
    "slug": "lag16",
    "binderType": "nanobody",
    "pdbId": "6LR7",
    "pdbUrl": "https://www.rcsb.org/structure/6LR7",
    "binderChainId": "B",
    "shortDescription": "Ultra-high affinity (0.5 nM) - binds opposite side from enhancer",
    "helpArticleSlug": "lag16",
    "discoveryYear": 2020,
    "approvalStatus": "research_tool",
    "sortOrder": 1,
    "scores": {
      "plddt": 90.69,
      "ptm": 0.717,
      "iptm": 0.264,
      "ipSaeScore": -0.264,
      "pdockq": 0.734,
      "pdockq2": 0.019,
      "lis": 0.044
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "G"
      ],
      "binderChains": [
        "A"
      ]
    }
  },
  {
    "id": "gfp-minimizer",
    "challengeId": "gfp",
    "name": "GFP Minimizer Nanobody",
    "slug": "gfp-minimizer",
    "binderType": "nanobody",
    "pdbId": "3G9A",
    "pdbUrl": "https://www.rcsb.org/structure/3G9A",
    "binderChainId": "B",
    "shortDescription": "Slightly dims GFP - opposite effect of enhancer",
    "helpArticleSlug": "gfp-minimizer",
    "discoveryYear": 2009,
    "approvalStatus": "research_tool",
    "sortOrder": 2,
    "scores": {
      "plddt": 95.39,
      "ptm": 0.849,
      "iptm": 0.407,
      "ipSaeScore": -0.407,
      "pdockq": 0.742,
      "pdockq2": 0.046,
      "lis": 0.297
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "G"
      ],
      "binderChains": [
        "N"
      ]
    }
  },
  {
    "id": "ly-cov555-spike",
    "challengeId": "spike-rbd",
    "name": "Bamlanivimab (LY-CoV555)",
    "slug": "bamlanivimab",
    "binderType": "antibody",
    "pdbId": "7KMG",
    "pdbUrl": "https://www.rcsb.org/structure/7KMG",
    "binderChainId": "B,C",
    "shortDescription": "First antibody EUA for COVID-19 - targets receptor binding motif",
    "helpArticleSlug": "bamlanivimab",
    "discoveryYear": 2020,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 89.99,
      "ptm": 0.569,
      "iptm": 0.507,
      "ipSaeScore": -0.507,
      "pdockq": 0.742,
      "pdockq2": 0.076,
      "lis": 0.365
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "binderChains": [
        "B",
        "C"
      ],
      "targetChains": [
        "inferred"
      ]
    }
  },
  {
    "id": "s309-spike",
    "challengeId": "spike-rbd",
    "name": "S309 (Sotrovimab parent)",
    "slug": "s309",
    "binderType": "antibody",
    "pdbId": "7R6X",
    "pdbUrl": "https://www.rcsb.org/structure/7R6X",
    "binderChainId": "H,L",
    "shortDescription": "Broadly neutralizing - targets conserved epitope across variants",
    "helpArticleSlug": "s309",
    "discoveryYear": 2020,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 88.08,
      "ptm": 0.424,
      "iptm": 0.29,
      "ipSaeScore": -0.29,
      "pdockq": 0.742,
      "pdockq2": 0.021,
      "lis": 0.059
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "C"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "ace2-decoy-spike",
    "challengeId": "spike-rbd",
    "name": "ACE2 Decoy Receptor",
    "slug": "ace2-decoy",
    "binderType": "natural",
    "pdbId": "6M0J",
    "pdbUrl": "https://www.rcsb.org/structure/6M0J",
    "binderChainId": "A",
    "shortDescription": "The natural receptor - basis for decoy therapeutic approaches",
    "helpArticleSlug": "ace2-decoy",
    "discoveryYear": 2020,
    "approvalStatus": "research_tool",
    "sortOrder": 2,
    "scores": {
      "plddt": 92.99,
      "ptm": 0.876,
      "iptm": 0.44,
      "ipSaeScore": -0.44,
      "pdockq": 0.742,
      "pdockq2": 0.054,
      "lis": 0.095
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "E"
      ],
      "binderChains": [
        "A"
      ]
    }
  },
  {
    "id": "adalimumab-tnf",
    "challengeId": "tnf-alpha",
    "name": "Adalimumab (Humira)",
    "slug": "adalimumab",
    "binderType": "antibody",
    "pdbId": "3WD5",
    "pdbUrl": "https://www.rcsb.org/structure/3WD5",
    "binderChainId": "H,L",
    "shortDescription": "Fully human antibody - was world's best-selling drug",
    "helpArticleSlug": "adalimumab",
    "discoveryYear": 2002,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 90.8,
      "ptm": 0.848,
      "iptm": 0.329,
      "ipSaeScore": -0.329,
      "pdockq": 0.742,
      "pdockq2": 0.025,
      "lis": 0.16
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A",
        "B"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "infliximab-tnf",
    "challengeId": "tnf-alpha",
    "name": "Infliximab (Remicade)",
    "slug": "infliximab",
    "binderType": "antibody",
    "pdbId": "4G3Y",
    "pdbUrl": "https://www.rcsb.org/structure/4G3Y",
    "binderChainId": "H,L",
    "shortDescription": "Chimeric antibody - different epitope than adalimumab",
    "helpArticleSlug": "infliximab",
    "discoveryYear": 1998,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 90.96,
      "ptm": 0.821,
      "iptm": 0.295,
      "ipSaeScore": -0.295,
      "pdockq": 0.742,
      "pdockq2": 0.023,
      "lis": 0.1
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "T"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "certolizumab-tnf",
    "challengeId": "tnf-alpha",
    "name": "Certolizumab (Cimzia)",
    "slug": "certolizumab",
    "binderType": "antibody",
    "pdbId": "5WUX",
    "pdbUrl": "https://www.rcsb.org/structure/5WUX",
    "binderChainId": "D,E",
    "shortDescription": "PEGylated Fab fragment - no Fc region",
    "helpArticleSlug": "certolizumab",
    "discoveryYear": 2008,
    "approvalStatus": "fda_approved",
    "sortOrder": 2,
    "scores": {
      "plddt": 86.03,
      "ptm": 0.507,
      "iptm": 0.262,
      "ipSaeScore": -0.262,
      "pdockq": 0.742,
      "pdockq2": 0.016,
      "lis": 0.05
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "C"
      ],
      "binderChains": [
        "A",
        "B"
      ]
    }
  },
  {
    "id": "atezolizumab-pdl1",
    "challengeId": "pd-l1",
    "name": "Atezolizumab (Tecentriq)",
    "slug": "atezolizumab",
    "binderType": "antibody",
    "pdbId": "5X8L",
    "pdbUrl": "https://www.rcsb.org/structure/5X8L",
    "binderChainId": "H,L",
    "shortDescription": "First FDA-approved PD-L1 inhibitor - revolutionized cancer therapy",
    "helpArticleSlug": "atezolizumab",
    "discoveryYear": 2016,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 87.65,
      "ptm": 0.379,
      "iptm": 0.285,
      "ipSaeScore": -0.285,
      "pdockq": 0.733,
      "pdockq2": 0.021,
      "lis": 0.035
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "durvalumab-pdl1",
    "challengeId": "pd-l1",
    "name": "Durvalumab (Imfinzi)",
    "slug": "durvalumab",
    "binderType": "antibody",
    "pdbId": "5X8M",
    "pdbUrl": "https://www.rcsb.org/structure/5X8M",
    "binderChainId": "B,C",
    "shortDescription": "Engineered Fc for reduced ADCC - different approach than atezolizumab",
    "helpArticleSlug": "durvalumab",
    "discoveryYear": 2017,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 97.43,
      "ptm": 0.834,
      "iptm": 0.312,
      "ipSaeScore": -0.312,
      "pdockq": 0.742,
      "pdockq2": 0.027,
      "lis": 0.164
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "trastuzumab-her2",
    "challengeId": "her2",
    "name": "Trastuzumab (Herceptin)",
    "slug": "trastuzumab",
    "binderType": "antibody",
    "pdbId": "1N8Z",
    "pdbUrl": "https://www.rcsb.org/structure/1N8Z",
    "binderChainId": "A,B",
    "shortDescription": "First targeted therapy for breast cancer - transformed treatment",
    "helpArticleSlug": "trastuzumab",
    "discoveryYear": 1998,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 94.65,
      "ptm": 0.698,
      "iptm": 0.487,
      "ipSaeScore": -0.487,
      "pdockq": 0.742,
      "pdockq2": 0.073,
      "lis": 0.171
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "C"
      ],
      "binderChains": [
        "A",
        "B"
      ]
    }
  },
  {
    "id": "pertuzumab-her2",
    "challengeId": "her2",
    "name": "Pertuzumab (Perjeta)",
    "slug": "pertuzumab",
    "binderType": "antibody",
    "pdbId": "1S78",
    "pdbUrl": "https://www.rcsb.org/structure/1S78",
    "binderChainId": "C,D,E,F",
    "shortDescription": "Binds different domain than trastuzumab - used in combination",
    "helpArticleSlug": "pertuzumab",
    "discoveryYear": 2012,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 89.67,
      "ptm": 0.596,
      "iptm": 0.351,
      "ipSaeScore": null,
      "pdockq": 0,
      "pdockq2": 0,
      "lis": 0
    },
    "scoringNote": "Boltz-2 does not predict the antibody-HER2 interface for this complex. The Fab folds correctly (H-L ipTM ~0.81) but does not dock to HER2. This is a known limitation - the crystal structure shows binding at a domain II epitope that differs from trastuzumab.",
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": true,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "H",
        "L"
      ],
      "note": "Sequence-only prediction with MSA. Interface not predicted despite correct Fab folding."
    }
  },
  {
    "id": "bevacizumab-vegf",
    "challengeId": "vegf-a",
    "name": "Bevacizumab (Avastin)",
    "slug": "bevacizumab",
    "binderType": "antibody",
    "pdbId": "1BJ1",
    "pdbUrl": "https://www.rcsb.org/structure/1BJ1",
    "binderChainId": "H,L",
    "shortDescription": "First anti-angiogenesis drug - blocks tumor blood vessel growth",
    "helpArticleSlug": "bevacizumab",
    "discoveryYear": 2004,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 92.86,
      "ptm": 0.547,
      "iptm": 0.265,
      "ipSaeScore": -0.265,
      "pdockq": 0.742,
      "pdockq2": 0.019,
      "lis": 0.1
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "Y"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "ranibizumab-vegf",
    "challengeId": "vegf-a",
    "name": "Ranibizumab (Lucentis)",
    "slug": "ranibizumab",
    "binderType": "antibody",
    "pdbId": "1CZ8",
    "pdbUrl": "https://www.rcsb.org/structure/1CZ8",
    "binderChainId": "H,L,X,Y",
    "shortDescription": "Fab fragment for eye injections - treats macular degeneration",
    "helpArticleSlug": "ranibizumab",
    "discoveryYear": 2006,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 96.28,
      "ptm": 0.833,
      "iptm": 0.292,
      "ipSaeScore": -0.292,
      "pdockq": 0.742,
      "pdockq2": 0.023,
      "lis": 0.152
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "V"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "tocilizumab-il6",
    "challengeId": "il-6",
    "name": "Tocilizumab (Actemra)",
    "slug": "tocilizumab",
    "binderType": "antibody",
    "pdbId": "8J6F",
    "pdbUrl": "https://www.rcsb.org/structure/8J6F",
    "binderChainId": "H,L",
    "shortDescription": "Targets IL-6 receptor - treats rheumatoid arthritis and cytokine storms",
    "helpArticleSlug": "tocilizumab",
    "discoveryYear": 2010,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 91.82,
      "ptm": 0.9,
      "iptm": 0.308,
      "ipSaeScore": -0.308,
      "pdockq": 0.742,
      "pdockq2": 0.024,
      "lis": 0.216
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "R"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "sarilumab-il6",
    "challengeId": "il-6",
    "name": "Sarilumab (Kevzara)",
    "slug": "sarilumab",
    "binderType": "antibody",
    "pdbId": "8IOW",
    "pdbUrl": "https://www.rcsb.org/structure/8IOW",
    "binderChainId": "H,L",
    "shortDescription": "Higher affinity than tocilizumab - fully human antibody",
    "helpArticleSlug": "sarilumab",
    "discoveryYear": 2017,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 96.74,
      "ptm": 0.88,
      "iptm": 0.86,
      "ipSaeScore": 3.48,
      "pdockq": 0.742,
      "pdockq2": 0.625,
      "lis": 0.875
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "I"
      ],
      "binderChains": [
        "H",
        "L"
      ],
      "note": "mmCIF format only (8IOW), auth chain IDs"
    }
  },
  {
    "id": "cetuximab-egfr",
    "challengeId": "egfr",
    "name": "Cetuximab (Erbitux)",
    "slug": "cetuximab",
    "binderType": "antibody",
    "pdbId": "1YY9",
    "pdbUrl": "https://www.rcsb.org/structure/1YY9",
    "binderChainId": "C,D",
    "shortDescription": "Chimeric antibody - first anti-EGFR therapy for colorectal cancer",
    "helpArticleSlug": "cetuximab",
    "discoveryYear": 2004,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 93.25,
      "ptm": 0.709,
      "iptm": 0.592,
      "ipSaeScore": -0.592,
      "pdockq": 0.742,
      "pdockq2": 0.138,
      "lis": 0.311
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "B"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "panitumumab-egfr",
    "challengeId": "egfr",
    "name": "Panitumumab (Vectibix)",
    "slug": "panitumumab",
    "binderType": "antibody",
    "pdbId": "5SX4",
    "pdbUrl": "https://www.rcsb.org/structure/5SX4",
    "binderChainId": "H,L",
    "shortDescription": "First fully human anti-EGFR antibody",
    "helpArticleSlug": "panitumumab",
    "discoveryYear": 2006,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 94.1,
      "ptm": 0.554,
      "iptm": 0.436,
      "ipSaeScore": -0.436,
      "pdockq": 0.742,
      "pdockq2": 0.054,
      "lis": 0.262
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "rituximab-cd20",
    "challengeId": "cd20",
    "name": "Rituximab (Rituxan)",
    "slug": "rituximab",
    "binderType": "antibody",
    "pdbId": "6Y90",
    "pdbUrl": "https://www.rcsb.org/structure/6Y90",
    "binderChainId": "H,L",
    "shortDescription": "First FDA-approved antibody for cancer (1997) - revolutionary therapy",
    "helpArticleSlug": "rituximab",
    "discoveryYear": 1997,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 92.22,
      "ptm": 0.64,
      "iptm": 0.271,
      "ipSaeScore": -0.271,
      "pdockq": 0.711,
      "pdockq2": 0.02,
      "lis": 0.023
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A100",
      "targetChains": [
        "G"
      ],
      "binderChains": [
        "H",
        "L"
      ],
      "note": "Large complex required A100"
    }
  },
  {
    "id": "obinutuzumab-cd20",
    "challengeId": "cd20",
    "name": "Obinutuzumab (Gazyva)",
    "slug": "obinutuzumab",
    "binderType": "antibody",
    "pdbId": "6Y9A",
    "pdbUrl": "https://www.rcsb.org/structure/6Y9A",
    "binderChainId": "H,L",
    "shortDescription": "Type II antibody - glycoengineered for enhanced cell killing",
    "helpArticleSlug": "obinutuzumab",
    "discoveryYear": 2013,
    "approvalStatus": "fda_approved",
    "sortOrder": 1,
    "scores": {
      "plddt": 89.86,
      "ptm": 0.907,
      "iptm": 0.53,
      "ipSaeScore": -0.53,
      "pdockq": 0.742,
      "pdockq2": 0.079,
      "lis": 0.409
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "C"
      ],
      "binderChains": [
        "A",
        "B"
      ]
    }
  },
  {
    "id": "evolocumab-pcsk9",
    "challengeId": "pcsk9",
    "name": "Evolocumab (Repatha)",
    "slug": "evolocumab",
    "binderType": "antibody",
    "pdbId": "3H42",
    "pdbUrl": "https://www.rcsb.org/structure/3H42",
    "binderChainId": "H,L",
    "shortDescription": "Lowers LDL cholesterol by 60% - prevents heart attacks",
    "helpArticleSlug": "evolocumab",
    "discoveryYear": 2015,
    "approvalStatus": "fda_approved",
    "sortOrder": 0,
    "scores": {
      "plddt": 89.52,
      "ptm": 0.828,
      "iptm": 0.44,
      "ipSaeScore": -0.44,
      "pdockq": 0.742,
      "pdockq2": 0.046,
      "lis": 0.251
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "D"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  },
  {
    "id": "s2b-insulin",
    "challengeId": "insulin",
    "name": "S2B (De Novo Designed)",
    "slug": "s2b-insulin",
    "binderType": "designed",
    "pdbId": "9DNN",
    "pdbUrl": "https://www.rcsb.org/structure/9DNN",
    "binderChainId": "C",
    "shortDescription": "AI-designed binder more potent than insulin - RFdiffusion + ProteinMPNN",
    "helpArticleSlug": "s2b-insulin",
    "discoveryYear": 2024,
    "approvalStatus": "de_novo_designed",
    "sortOrder": 0,
    "scores": {
      "plddt": 84.37,
      "ptm": 0.455,
      "iptm": 0.25,
      "ipSaeScore": -0.25,
      "pdockq": 0.741,
      "pdockq2": 0.016,
      "lis": 0.465
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "A",
        "B"
      ],
      "binderChains": [
        "C"
      ]
    }
  },
  {
    "id": "oxi005-insulin",
    "challengeId": "insulin",
    "name": "OXI-005 Analytical Antibody",
    "slug": "oxi005",
    "binderType": "antibody",
    "pdbId": "6Z7Y",
    "pdbUrl": "https://www.rcsb.org/structure/6Z7Y",
    "binderChainId": "C,D",
    "shortDescription": "High-precision research antibody used in insulin detection assays",
    "helpArticleSlug": "oxi005",
    "discoveryYear": 2020,
    "approvalStatus": "research_tool",
    "sortOrder": 1,
    "scores": {
      "plddt": 90.11,
      "ptm": 0.608,
      "iptm": 0.262,
      "ipSaeScore": -0.262,
      "pdockq": 0.742,
      "pdockq2": 0.018,
      "lis": 0.105
    },
    "inferenceParams": {
      "method": "boltz2",
      "boltzVersion": "0.4.x",
      "diffusionSamples": 1,
      "useMsa": false,
      "outputFormat": "pdb",
      "gpu": "A10G",
      "targetChains": [
        "I"
      ],
      "binderChains": [
        "H",
        "L"
      ]
    }
  }
]